4.7 Article

Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis

期刊

NEUROLOGY
卷 88, 期 1, 页码 87-92

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000003418

关键词

-

资金

  1. NHS England
  2. Children's Tumor Foundation
  3. National Institute for Health Research [NF-SI-0513-10076] Funding Source: researchfish
  4. Worldwide Cancer Research [12-0275] Funding Source: researchfish

向作者/读者索取更多资源

Objective: To determine the specificity of the current clinical diagnostic criteria for neurofibromatosis type 2 (NF2) relative to the requirement for unilateral vestibular schwannoma (VS) and at least 2 other NF2-related tumors. Methods: We interrogated our Manchester NF2 database, which contained 205 individuals meeting NF2 criteria who initially presented with a unilateral VS. Of these, 83 (40.7%) went on to develop a contralateral VS. We concentrated our genetic analysis on a group of 70 who initially fulfilled NF2 criteria with a unilateral vestibular schwannoma and at least 2 additional nonintradermal schwannomas. Results: Overall, 5/70 (7%) individuals with unilateral VS and at least 2 other schwannomas had a pathogenic or likely pathogenic LZTR1 mutation. Twenty of the 70 subsequently developed bilateral disease. Of the remaining 50, 5 (10%) had a germline LZTR1 mutation, equivalent to the number (n = 5) with a germline NF2 mutation. Conclusions: The most common etiology for unilateral VS and 2 additional NF2-associated tumors in this cohort was mosaic NF2. Germline LZTR1 and germline NF2 mutations were equally common in our cohort. This indicates that LZTR1 must be considered when making a diagnosis of NF2 in the presence of unilateral VS in individuals without a germline NF2 mutation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2

Sue Philpott, Maria Raikou, Ranjit Manchanda, Michelle Lockley, Naveena Singh, Malcolm Scott, D. Gareth Evans, Julian Adlard, Munaza Ahmed, Richard Edmondson, Emma Roisin Woodward, Athena Lamnisos, Janos Balega, Angela F. Brady, Aarti Sharma, Louise Izatt, Anjana Kulkarni, Vishakha Tripathi, Joyce S. Solomons, Kevin Hayes, Helen Hanson, Katie Snape, Lucy Side, Steve Skates, Alistair McGuire, Adam N. Rosenthal

Summary: This study aimed to evaluate the effectiveness and cost-effectiveness of ovarian cancer surveillance in BRCA1/2-heterozygous women deferring risk-reducing surgery. The results showed that surveillance in a real-world setting was feasible and demonstrated similar performance to research trials, effectively down-staging ovarian cancer and saving costs.

JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome

Linda A. J. Hendricks, Nicoline Hoogerbrugge, Arjen R. Mensenkamp, Joan Brunet, Roser Lleuger-Pujol, Hildegunn Hoberg-Vetti, Marianne Tveit Haavind, Giovanni Innella, Daniela Turchetti, Stefan Aretz, Isabel Spier, Marc Tischkowitz, Arne Jahn, Thera P. Links, Maran J. W. Olderode-Berends, Ana Blatnik, Edward M. Leter, D. Gareth Evans, Emma R. Woodward, Verena Steinke-Lange, Violetta C. Anastasiadou, Chrystelle Colas, Marie-Charlotte Villy, Patrick R. Benusiglio, Anna Gerasimenko, Valeria Barili, Maud Branchaud, Claude Houdayer, Bianca Tesi, M. Omer Yazicioglu, Rachel S. van der Post, Janneke H. M. Schuurs-Hoeijmakers, Janet R. Vos, Liselotte P. van Hest, Muriel A. Adank, Floor Duijkers, Maartje Nielsen, Katja C. J. Verbeek, Yvette van Ierland, Jacques C. Giltay

Summary: PTEN Hamartoma Tumor Syndrome (PHTS) is a rare syndrome with a broad phenotypic spectrum, including increased risks of breast, endometrial, and thyroid cancer. This study aimed to provide more accurate and personalized cancer risks. The results showed that PHTS patients, especially females, have a significantly higher risk of breast, endometrial, and thyroid cancer.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Clinical Neurology

Genome-wide association analysis identifies a susceptibility locus for sporadic vestibular schwannoma at 9p21

Katherine Sadler, John Bowes, Charlie F. Rowlands, Cristina Perez-Becerril, C. Mwee van der Meer, Andrew T. King, Scott A. Rutherford, Omar N. Pathmanaban, Charlotte Hammerbeck-Ward, Simon K. W. Lloyd, Simon R. Freeman, Ricky Williams, Cathal John Hannan, Daniel Lewis, Steve Eyre, D. Gareth Evans, Miriam J. Smith

Summary: A genome-wide association study revealed that rs1556516 in the 9p21.3 region is associated with the risk of vestibular schwannoma. The dysregulation of CDKN2B-AS1 and CDKN2A/B genes in this region has been linked to multiple pathologies, and these genes have been shown to influence each other's expression. The recurrent associations of the 9p21.3 region with known oncogenic pathways provide compelling evidence for its involvement in vestibular schwannoma tumorigenesis.
Article Genetics & Heredity

Differential rates of germline heterozygote and mosaic variants in NF2 may show varying propensity for meiotic or mitotic mutation

D. Gareth Evans, George J. Burghel, Miriam Jane Smith

Summary: NF2-related schwannomatosis is a genetic condition that causes multiple benign tumors of the nervous system. It is caused by pathogenic variants in the NF2 gene, with six specific CpG nonsense variants being responsible for a majority of the cases. The de novo heterozygote to mosaicism ratio of one of these variants, NF2 c.586C>T; p.(Arg196Ter), is higher compared to the others, possibly due to variations in mutation rates during meiosis and mitosis.

JOURNAL OF MEDICAL GENETICS (2023)

Article Genetics & Heredity

Germline mismatch repair (MMR) gene analyses from English NHS regional molecular genomics laboratories 1996-2020: development of a national resource of patient-level genomics laboratory records

Lucy Loong, Catherine Huntley, Fiona McRonald, Francesco Santaniello, Joanna Pethick, Bethany Torr, Sophie Allen, Oliver Tulloch, Shilpi Goel, Brian Shand, Tameera Rahman, Margreet Luchtenborg, Alice Garrett, Richard Barber, Tin Bedenham, David Bourn, Kirsty Bradshaw, Claire Brooks, Jonathan Bruty, George J. Burghel, Samantha Butler, Chris Buxton, Alison Callaway, Jonathan Callaway, James Drummond, Miranda Durkie, Joanne Field, Lucy Jenkins, Terri P. McVeigh, Roger Mountford, Rodney Nyanhete, Evgenia Petrides, Rachel Robinson, Tracy Scott, Victoria Stinton, James Tellez, Andrew J. Wallace, Laura Yarram-Smith, Kate Sahan, Nina Hallowell, Diana M. Eccles, Paul Pharoah, Marc Tischkowitz, Antonis C. Antoniou, D. Gareth Evans, Fiona Lalloo, Gail Norbury, Eva Morris, John Burn, Steven Hardy, Clare Turnbull

Summary: This study describes the national patterns of NHS analysis of MMR genes in England using individual-level data submitted to NDRS by regional molecular genetics laboratories. The NDRS MMR dataset is a unique national amalgamation of clinical and genomic patient data, enabling data linkage to other national datasets. This resource can enable longitudinal research and form the basis of a live national genomic disease registry.

JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?

Robert D. D. Morgan, George J. J. Burghel, Nicola Flaum, Michael Bulman, Philip Smith, Andrew R. R. Clamp, Jurjees Hasan, Claire L. L. Mitchell, Zena Salih, Emma R. R. Woodward, Fiona Lalloo, Emma J. J. Crosbie, Richard J. J. Edmondson, Helene Schlecht, Gordon C. C. Jayson, D. Gareth R. Evans

Summary: Approximately 15% of patients diagnosed with high-grade non-mucinous epithelial ovarian cancer (EOC) have a germline BRCA1/2 mutation, with somatic mutations occurring more frequently in patients aged >= 80. Germline BRCA1/2 testing in this age group can be reserved for those with a detectable tumour BRCA1/2 mutation. Testing for tumour BRCA1/2 and homologous recombination deficiency is sufficient for patients aged >= 80 with non-mucinous high-grade EOC.

CANCERS (2023)

Review Medicine, General & Internal

ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1

Charlotte Carton, D. Gareth Evans, Ignacio Blanco, Reinhard E. Friedrich, Rosalie E. Ferner, Said Farschtschi, Hector Salvador, Amedeo A. Azizi, Victor Mautner, Claas Roehl, Sirkku Peltonen, Stavros Stivaros, Eric Legius, Rianne Oostenbrink

Summary: This study aims to integrate information on NF1-associated tumors to assist healthcare professionals in tumor surveillance of NF1 individuals. Personalized and targeted tumor management proposals have been defined to ensure appropriate care for those in need.

ECLINICALMEDICINE (2023)

Article Oncology

Perspectives on the implications of carrying putative pathogenic variants in the medulloblastoma predisposition genes ELP1 and GPR161

Miriam J. Smith, Emma R. Woodward, D. Gareth Evans

Summary: Recent genetic sequencing studies have identified loss-of-function variants in the ELP1 and GPR161 genes as causes of childhood medulloblastoma. Although there is speculation that GPR161 may also cause Gorlin syndrome, the projected risks of developing medulloblastoma with these gene variants are relatively low and do not warrant MRI screening in infants.

FAMILIAL CANCER (2023)

Article Genetics & Heredity

Optimization of polygenic risk scores in BRCA1/2 pathogenic variant heterozygotes in epithelial ovarian cancer

Nicola Flaum, John Bowes, Miriam J. Smith, Emma J. Crosbie, Richard Edmondson, Artitaya Lophatananon, D. Gareth Evans

Summary: This study evaluated the association between BRCA1/2 heterozygotes and familial epithelial ovarian cancer (EOC) by constructing modified polygenic risk scores (PRS) validated by Barnes et al. It was found that combining PRS with age, family history, and hormonal factors significantly improved the discrimination ability of EOC risk, although the contribution of PRS was small. Larger prospective studies are needed to assess the usefulness of combined-PRS models in risk-reducing decisions.

GENETICS IN MEDICINE (2023)

Article Health Policy & Services

The role of knowledge, primary care and community engagement to improve breast-screening access for Pakistani women in the United Kingdom: A secondary analysis of a qualitative study

Hooran M. Khattak, Victoria G. Woof, David P. French, Louise S. Donnelly, Helen Ruane, Fiona Ulph, Nadeem Qureshi, Nasaim Khan, D. Gareth Evans, Kathryn A. Robb

Summary: The objective of this study was to improve access to breast screening for British-Pakistani women by understanding their knowledge of breast cancer and the role of primary care and community networks. The findings suggested the need for co-produced strategies, collaboration with General Practitioners, and community engagement to increase knowledge and support informed choices about screening.

JOURNAL OF HEALTH SERVICES RESEARCH & POLICY (2023)

Article Medicine, General & Internal

Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials

Neill K. J. Adhikari, Madiha LOVIT-COVID Investigators, Bharath Kumar Canadian Critical Care Trials Grp, Rashan REMAP-CAP Investigators, Madiha Hashmi, Bharath Kumar Tirupakuzhi Vijayaraghavan, Rashan Haniffa, Abi Beane, Steve A. Webb, Derek C. Angus, Anthony C. Gordon, Deborah J. Cook, Gordon H. Guyatt, Lindsay R. Berry, Elizabeth Lorenzi, Paul R. Mouncey, Carly Au, Ruxandra Pinto, Julie Menard, Sheila Sprague, Marie-Helene Masse, David T. Huang, Daren K. Heyland, Alistair D. Nichol, Colin J. McArthur, Angelique de Man, Farah Al-Beidh, Djillali Annane, Matthew Anstey, Yaseen M. Arabi, Marie-Claude Battista, Scott Berry, Zahra Bhimani, Marc J. M. Bonten, Charlotte A. Bradbury, Emily B. Brant, Frank M. Brunkhorst, Aidan Burrell, Meredith Buxton, Maurizio Cecconi, Allen C. Cheng, Dian Cohen, Matthew E. Cove, Andrew G. Day, Lennie P. G. Derde, Michelle A. Detry, Lise J. Estcourt, Elizabeth O. Fagbodun, Mark Fitzgerald, Herman Goossens, Cameron Green, Alisa M. Higgins, Thomas E. Hills, Nao Ichihara, Devachandran Jayakumar, Salmaan Kanji, Muhammad Nasir Khoso, Patrick R. Lawler, Roger J. Lewis, Edward Litton, John C. Marshall, Daniel F. McAuley, Anna McGlothlin, Shay P. McGuinness, Zoe K. McQuilten, Bryan J. McVerry, Srinivas Murthy, Rachael L. Parke, Jane C. Parker, Luis Felipe Reyes, Kathryn M. Rowan, Hiroki Saito, Nawal Salahuddin, Marlene S. Santos, Christina T. Saunders, Christopher W. Seymour, Manu Shankar-Hari, Timo Tolppa, Tony Trapani, Alexis F. Turgeon, Anne M. Turner, Andrew A. Udy, Frank L. van de Veerdonk, Ryan Zarychanski, Francois Lamontagne

Summary: The efficacy of using vitamin C for COVID-19 treatment in critically ill and non-critically ill patients is uncertain.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Meeting Abstract Oncology

Impact of time between last childbirth and diagnosis of early-onset breast cancer on survival in germline BRCA1/2 carriers

Zhenzhen Zhang, Shangyuan Ye, D. Gareth Evans, Pepper Schedin

CANCER RESEARCH (2023)

Meeting Abstract Oncology

A model to assess the utility of risk-based screening algorithms

Emma C. Atakpa, Jack Cuzick, Stephen W. Duffy, D. Gareth Evans, Sacha J. Howell, Adam R. Brentnall

CANCER RESEARCH (2023)

Article Clinical Neurology

The comparable tumour microenvironment in sporadic and NF2-related schwannomatosis vestibular schwannoma

Grace E. Gregory, Adam Paul Jones, Michael J. Haley, Christopher Hoyle, Leo A. H. Zeef, I-Hsuan Lin, David J. Coope, Andrew T. King, D. Gareth Evans, Pawel Paszek, Kevin N. Couper, David Brough, Omar N. Pathmanaban

Summary: Bilateral vestibular schwannoma is a characteristic feature of NF2-related schwannomatosis, which is associated with multiple surgical interventions, radiotherapy, and off-label use of bevacizumab. Unilateral vestibular schwannoma occurs sporadically in non-NF2-related schwannomatosis patients without drug treatment options. Tumour-infiltrating immune cells, especially macrophages and T-cells, play a role in the growth of vestibular schwannoma and show similarities between sporadic and NF2-related schwannomatosis tumours. However, there are differences in tumour presentation and patient characteristics between these two conditions. This study compared the tumour microenvironment of sporadic and NF2-related schwannomatosis vestibular schwannoma and found strong similarities in the immune profiles.

BRAIN COMMUNICATIONS (2023)

Article Clinical Neurology

Intraoperative diagnosis of facial schwannomas: a multicenter summation of clinical experience, preoperative avoidance, and intraoperative management protocol

Daniel Lewis, Cathal John Hannan, Aaron R. Plitt, Lauren Rose Snyder, George Richardson, Andrew T. King, Charlotte Hammerbeck-Ward, Omar N. Pathmanaban, Brian A. Neff, Colin L. Driscoll, Jamie J. Van Gompel, Matthew L. Carlson, John I. Lane, Simon K. Lloyd, Simon R. Freeman, Roger D. Laitt, Sarah Abdulla, Rekha Siripurapu, Gillian M. Potter, Michael J. Link, Scott A. Rutherford

Summary: Preoperative differentiation between facial nerve schwannoma (FNS) and vestibular schwannoma (VS) can be challenging. This study provides clinical and imaging features to distinguish FNS from VS and offers recommendations for surgical decision-making in intraoperatively diagnosed FNS.

JOURNAL OF NEUROSURGERY (2023)

暂无数据